Company intelligence / Profile preview
Glycologix
Boston, Massachusetts, USAglycologix.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Phase 1
01
Overview
Glycologix’s lead program, GLX‑100, is a locally delivered chondroitin sulfate-based biopolymer for interstitial cystitis/bladder pain syndrome. The company’s technology platform is designed to mimic the structure and function of natural proteoglycans to restore hydration, lubrication, and structural support in soft tissues. The platform has potential applications across multiple large unmet medical needs; however, detailed clinical results have not been publicly disclosed as of June 2025.
- Therapeutic areas
- NephrologyOtherDermatologyRheumatologyOphthalmologyNeurology
- Modalities
- BiopolymerSynthetic proteoglycan mimicChondroitin sulfate-based biopolymerBiomaterial therapy (locally delivered)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Glycologix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glycologix.